InvestorsObserver
×
News Home

Do Traders Think Seagen Inc (SGEN) Can Turn Around Thursday?

Thursday, May 06, 2021 11:55 AM | InvestorsObserver Analysts

Mentioned in this article

Do Traders Think Seagen Inc (SGEN) Can Turn Around Thursday?

Overall market sentiment has been down on Seagen Inc (SGEN) stock lately. SGEN receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bearish
Seagen Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SGEN!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.

Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.

InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.

Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With SGEN Stock Today?

Seagen Inc (SGEN) stock is trading at $135.81 as of 11:53 AM on Thursday, May 6, a rise of $0.73, or 0.54% from the previous closing price of $135.08. Volume today is light. So far 552,060 shares have traded compared to average volume of 956,250 shares. The stock has traded between $133.68 and $136.00 so far today.

To see InvestorsObserver's Sentiment Score for Seagen Inc click here.

More About Seagen Inc

Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Click Here to get the full Stock Score Report on Seagen Inc (SGEN) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App